Artivion reported an 11% increase in revenue to $89.3 million for the second quarter of 2023. The company's non-GAAP net income was $2.3 million, or $0.06 per share, compared to a non-GAAP net loss of ($1.3) million, or ($0.03) per share for the second quarter of 2022. The company is raising its revenue guidance range and now expects to achieve constant currency revenue growth of between 10% and 12% for the full year 2023 compared to 2022.
Revenue increased by 11% to $89.3 million compared to Q2 2022.
Net loss was ($3.4) million or ($0.08) per share; non-GAAP net income was $2.3 million or $0.06 per share
Aortic stent graft revenues increased 19% on a constant currency basis.
Received PerClot PMA approval and commenced shipping product to Baxter
Artivion expects to achieve constant currency revenue growth of between 10% and 12% for the full year 2023 compared to 2022. The Company expects revenues to be in a range of $342.0 million and $350.0 million. Additionally, Artivion continues to expect adjusted EBITDA to increase greater than 25% in 2023 compared to 2022, resulting in adjusted EBITDA in excess of $52.0 million for 2023.
Analyze how earnings announcements historically affect stock price performance